Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

Author: j3ff1

Home Articles Posted by j3ff1
113 posts, 0 comments

2/1/23 – ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits

February 1, 2023j3ff1
Read More

1/23/23 – RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois

January 23, 2023j3ff1
Read More

1/12/23 – RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform

January 23, 2023j3ff1
Read More

12/5/22 – RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development

December 5, 2022j3ff1
Read More

11/17/22 – RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Sleep Apnea

November 17, 2022j3ff1
Read More

11/10/22 – RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4

November 10, 2022j3ff1
Read More

11/7/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th Meridian Drug Discovery Summit

November 8, 2022j3ff1
Read More

9/7/22 – ResolutionRx Slide Deck Re-Purposing Dronabinol

September 25, 2022j3ff1
Read More

8/8/22 – RespireRx Pharmaceuticals Inc. Announces that Sleep Review has Discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition

August 8, 2022j3ff1
Read More

5/24/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit

May 24, 2022j3ff1
Read More

Posts navigation

1 2 3 4 … 12 >

RespireRx Organization Structure

  • RespireRx Organization Structure
  • Arnold S. Lippa, PhD
    • Richard Purcell
    • David Dickason
    • James Cook
    • Jeffrey M. Witkin
    • Rok Cerne
  • Jeff Margolis
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.